RaySearch Laboratories Shows Remarkable Growth in Q1 2025 Financials and Innovations

RaySearch Laboratories' Promising Q1 2025 Report

In its recently released interim report for the first quarter of 2025, RaySearch Laboratories has demonstrated remarkable progress in both financial performance and innovative developments within the medical technology sector. The report covers the period from January 1 to March 31, 2025, and highlights key metrics such as order intake, net sales, and advancements in cancer treatment technologies.

Financial Highlights

RaySearch's order intake for the first quarter amounted to SEK 409.6 million, showing a significant increase from SEK 238.5 million in the same period last year. This remarkable growth underscores the company's strengthening market position. In terms of net sales, RaySearch reported SEK 331.7 million, up from SEK 257.2 million, indicating a promising upward trend in business performance.

The operating profit also saw an increase, reaching SEK 74.8 million compared to SEK 45.8 million in the previous year. Profit after tax stands at SEK 56.8 million, showing a rise from SEK 36.7 million. Additionally, earnings per share saw a positive change, with pre-and post-dilution earnings reaching SEK 1.66, up from SEK 1.07. Cash flow from operating activities was reported at SEK 146.8 million, though slightly down from SEK 167.3 million in the previous year.

An important figure to note is the order backlog, which totaled SEK 1,734.4 million at the end of the quarter, compared to SEK 1,848.0 million from last year. This backlog illustrates a robust pipeline of future business opportunities for RaySearch.

Major Developments in Q1

Significantly, RaySearch has surpassed the milestone of 1,100 global radiation therapy clinics choosing its flagship treatment planning system, RayStation. This growing adoption is a testament to the effectiveness and reliability of RaySearch’s solutions.

Additionally, RaySearch has successfully secured its first order for DrugLog, marking a major collaboration with Medim. This order came after Medim won a tender from Poland's largest children's hospital, The Children's Memorial Health Institute.

Another noteworthy development is the order placed by the Heyou Hospital, a renowned carbon ion center in China. This order, valued at approximately RMB 51 million (around SEK 77 million), stands as the third largest in RaySearch's history. The company recognized revenue of RMB 18 million (approximately SEK 26 million) in this period, further validating its strategic growth initiatives.

Leadership Changes

Furthermore, in March 2025, Johan Löf, the CEO and board member of RaySearch, executed a notable sale of 2 million B-shares in the company, accounting for 5.8 percent of the total share capital. This was done through a conversion process, resulting in RaySearch having a total of 85,177,548 votes and 34,282,773 registered shares. After this transaction, Johan Löf retains 40.5 percent of voting rights and 10.2 percent of the overall share capital, showing his continued significant stake in the company.

Innovations After Q1

Following the first quarter, in May 2025, RaySearch unveiled its latest version of RayStation, known as RayStation v2025. This release signifies ongoing commitment to innovation and quality in cancer treatment planning. Notably, The Royal Marsden NHS Foundation Trust in the UK has embraced this technology, treating its first patient using a groundbreaking workflow enabled by a new adaptive replanning module released with the update.

In summary, RaySearch Laboratories is on a solid growth trajectory, showcasing strong financial results and industry-leading innovations that enhance the quality of cancer care globally. As they expand their technological offerings and increase their presence in international markets, RaySearch solidifies its reputation as a pioneer in the medical technology landscape.